In the U.S., Biosimilars Run Into More Roadblocks
In a recent op-ed in the Wall Street Journal Peter Bach asks whether it's time to give up on biosimilars. One might counter by saying don't throw out the baby with the bathwater. While biosimilar uptake has not been as robust as was hoped initially, .
According to Rick Lozano (Vice President, Biosimilars and Integrated Business Development, AmerisourceBergen), "across the supply chain incentives are not aligned." For the purpose of establishing a truly competitive market there needs to be an "even playing field" for biosimilars and originator biologics. Lingering patent disputes and court decisions, such as the ruling on Enbrel (etanercept) "create delays and distractions," Lozano says.
For the full article, visit Forbes.